Monday was Gyn Cancer Poster day at #ASCO24.
Here are a few posters along with their study conclusions that I found most interesting this year.
Tumor-informed ctDNA as an objective marker for postoperative residual disease in epithelial ovarian cancer. #5544
"The present tumor-informed dPCR SV fingerprint ctDNA approach demonstrated feasibility with remarkably high detection rates pre- and postoperatively. Postoperative ctDNA levels differed substantially based on postoperative tumor residuals. These findings suggest that this personalized approach could be used to develop a dPCR SV detection assay and may have clinical utility for postoperative MRD evaluation in patients with primary advanced HGSOC."
Through the years there has been a lot of talk regarding detecting circulating tumor DNA in the blood of patients. This study showed ctDNA could be used as a marker in ovarian cancer .
Differences in physical and emotional distress amongst patients undergoing neoadjuvant chemotherapy versus surgery for advanced ovarian cancer: Patient-reported outcomes at diagnosis. #5546
"Advanced OC patients have high psychosocial needs, with NACT patients reporting severe perceived symptoms on PRO measures. The PSS-10 may be a valuable screening tool for patients undergoing NACT to prioritize supportive care services."
Use of cell-free DNA
from ascites to identify variants and tumour evolution in a cohort of
patients with advanced ovarian cancer. #5547
This work "demonstrated the reliability of using cfDNA from ascites for molecular profiling, allowing a liquid biopsy of ovarian cancer when tumor tissue access may be restricted. This approach improves accessibility of tumour material, allowing capture of clinically actionable mutations prior to surgery or upon recurrence, following tumour evolution."
There is a difference between cfDNA and ctDNA- "The ctDNA is the fraction of cfDNA that originates from tumor cells, which comes from three sources: apoptosis, necrosis, and active secretion. While ctDNA can come from apoptosis with fragment lengths similar to healthy patients, ctDNA is more fragmented or shorter than cfDNA [20,32,33]. " Source : NIH
Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer. #5548
"Cisplatin in combination with gemcitabine demonstrates activity
regardless of platinum sensitivity status in patients with recurrent
ovarian cancer. However, longer platinum-free interval is associated
with improved response to this therapy".
Evaluation of a novel extracellular vesicle (EV) based ovarian cancer (OC) screening test in asymptomatic postmenopausal women. #5553
"The OC Test is capable of highly sensitive and specific detection of HGSC in asymptomatic postmenopausal women one year prior to Dx and can detect HGSC up to three years prior to Dx with superior sensitivity and specificity compared to CA125."
Finding a screening test for ovarian cancer is important. This is a different approach looking at extracellular vesicles. " Extracellular vesicles (EVs) are generated
and released by cells as part of various physiological and pathological
processes, including the progression of ovarian cancer. "Source Science Direct
The BEV1L study: Do
real-world outcomes associated with the addition of bevacizumab to
first-line chemotherapy in patients with ovarian cancer reinforce
clinical trial findings? #5563
"This real world study provides support for findings from ICON7 and GOG-0218, suggesting that the benefit of adding bev to first line chemotherapy may be limited to patients with high-risk clinical factors ( Stage IV disease or stage III disease with visible residual disease or no evidence of surgery). "
Association of physical activity with self-reported quality of life after primary chemotherapy for ovarian cancer. #5574
"We observed positive associations between health tracker physical activity data and pt-reported QOL. Stronger associations were observed in younger pts. Interventions aimed at increasing physical activity may have broader quality of life benefits for individuals with ovarian cancer."
When I was first diagnosed I was told to rest during chemotherapy treatment. When I recurred a few years later I was told to try to walk each day. I'm glad that theren is now data saying that exercise has QOL benefits.
Artificial intelligence to
predict homologous recombination deficiency in ovarian cancer from
whole-slide histopathological images. #5578
"By harnessing the power of deep neural networks (DNN), we provide a rapid and scalable solution for HRD prediction, circumventing the limitations of traditional molecular assays. Successful integration of this deep learning model into routine pathology workflows could significantly enhance diagnostic efficiency, reduce the turnaround time and financial cost compared with molecular assay. "
There were a number of talks at ASCO related to the use of AI. HRD is a marker used to manage ovarian cancer patient treatments.
Germline genetic profiles of women with ovarian malignancies: A Myriad Collaborative Research Registry study #5585
"Based on this large registry, our data showed that over 15% of patients with ovarian malignancies have mutations in BRCA (12.5%) or Lynch genes (2.6%) with varying prevalence by race, age, and tumor site. Noted disparities indicate the importance of universal testing in patients with epithelial ovarian malignancies."
I knew that Lynch syndrome was associated with endometrial cancer but I did not associate ovarian cancer with Lynch sydrome.
